OAKS Study: 48-Month Results – Derby & Gale Open-Label Extension

Pegcetacoplan for Geographic Atrophy: A Definitive Guide to the 48-Month Data adn the Future of GA Treatment (August 9, 2025)

Geographic atrophy (GA) is a leading cause ⁣of irreversible vision ‍loss, and for ⁣years,⁢ patients have faced a grim⁢ prognosis with limited treatment options.However, the landscape is rapidly changing.‍ Recent data presented at the ASRS 2025 conference in Long beach, California, by Dr. Roger A. Goldberg ⁣of Bay Area Retina Associates, offers compelling evidence for the long-term efficacy and safety of pegcetacoplan in slowing the progression of this devastating disease. This article provides a extensive overview of the 48-month results from the⁤ DERBY and OAKS clinical trials, including the ‍crucial‍ GALE open-label extension study, and explores what this means for‍ patients and the ⁤future of GA treatment.

Understanding Geographic Atrophy: The⁤ Silent Thief of Vision

Geographic‍ atrophy is the ⁣late stage of age-related macular ⁣degeneration (AMD), affecting the central part of the retina responsible for sharp, central vision. Unlike the “wet” form of AMD, which involves abnormal blood ⁤vessel growth, GA is characterized by the progressive⁣ death of retinal cells, creating expanding areas of atrophy – the “geographic” appearance that gives the condition its⁣ name. ⁣This ⁢loss of retinal tissue leads to a gradual decline in visual acuity,⁣ impacting daily activities like reading, driving, and recognizing faces.

Currently, an estimated 1.5 million people in the ⁢US live with GA, and that number is projected⁣ to rise dramatically as the population ages.⁢ Until recently, management focused on supportive care and low-vision aids. The approval of pegcetacoplan⁤ represents a paradigm shift, offering the first treatment capable of demonstrably slowing ‍disease progression.

The DERBY and OAKS Trials: Laying the Groundwork

The foundation for pegcetacoplan’s approval rests ⁢on the results of the Phase 3 DERBY and OAKS clinical trials. These randomized,⁢ double-masked, placebo-controlled studies evaluated the efficacy and ⁣safety of monthly pegcetacoplan injections in patients with GA. Both trials demonstrated statistically significant reductions in GA area growth compared to placebo over 12 months. DERBY: Focused on patients with GA affecting the non-central retina.
OAKS: Enrolled patients with GA involving the center of the macula, including the fovea – the area responsible for the sharpest vision.

The positive results from these trials lead to the FDA approval ⁤of pegcetacoplan in February 2023, marking ⁤a significant milestone in the treatment of GA. Though, the initial 12-month data only provided a snapshot of the ⁢treatment’s potential. The‍ real question was: would the benefits⁢ persist over the long term?

GALE: 48-Month Data Reveals Sustained Efficacy and Growing Benefits

The GALE (Geographic Atrophy Long-term Extension) study was designed to answer that question.⁣ This open-label ‍extension study enrolled patients who had completed the DERBY and OAKS trials, allowing them to continue receiving⁣ pegcetacoplan treatment for an extended period. Dr. Goldberg’s presentation at ASRS 2025 showcased the remarkable 48-month data from GALE,confirming not only the durability of the treatment effect but also its ⁣potential to increase over time.

Key Findings⁤ from⁤ the 48-Month GALE⁤ Data:

Significant Tissue Preservation: Patients receiving⁣ monthly⁤ pegcetacoplan treatment ‍preserved an average of 3.16 square millimeters of retinal tissue over four years in ⁣the non-subfoveal population. Those ⁢treated every other month preserved 2.77 square millimeters. This represents⁣ a substantial slowing of disease progression compared to the natural history of GA,⁤ where significant tissue loss is expected.
Time-Dependent Efficacy: Perhaps⁣ the most encouraging finding was the⁤ observation that pegcetacoplan’s effectiveness improved over time. Greater tissue preservation and slower GA growth were observed in years 3 and 4 compared to the initial ‍2 years of treatment. This suggests that⁣ continuous treatment allows ⁣the drug to exert a more profound and lasting effect on the underlying disease process.
The Critical Importance of early ⁢Intervention: The data unequivocally demonstrated that delaying treatment‍ significantly diminishes the benefits. Patients who waited two years before initiating⁢ pegcetacoplan treatment only ‍preserved 1.1 square millimeters of retinal tissue – a stark contrast to those receiving continuous treatment. This underscores the need for prompt ‍diagnosis and treatment initiation to maximize ⁢the potential for vision preservation.
Microperimetry Data: protecting Central Vision: microperimetry,a specialized test that measures⁣ retinal sensitivity,revealed a compelling 35% risk reduction in⁢ the progression of absolute scotomas⁢ (blind spots) in early-treated patients. This benefit was particularly pronounced in the central ‍4 and 16 loci of vision,areas